Abstract
The present study aimed to examine (1) whether the role of the opioid receptor in ischemic preconditioning (PC) is consistent regardless of the duration of ischemic insult and (2) which opioid receptor subtype contributes to PC. In the first series of experiments, the effects of PC, a nonselective opioid receptor antagonist (naloxone), and their combination on the infarct size after various durations of ischemia were assessed. In anesthetized, open-chest rats, the coronary artery was occluded for 20, 30, or 40 minutes to induce infarction and was reperfused for 3 hours, PC was performed with two cycles of 5-minute ischemia followed by 5-minute reperfusion before the sustained ischemia. At 25 minutes before the ischemia, naloxone was injected alone or in combination with subsequent PC. Infarct size was determined by tetrazolium staining and was expressed as a percentage of the risk area size (%IS/RA). In the second series of experiments, the effects of a δ-receptor selective antagonist, naltrindole (NTI), and a κ-receptor selective antagonist, nor-binaltrophimine (nor-BNI), on PC before 30-minute coronary occlusion were assessed. In untreated controls, %IS/RA was 53.1 ± 3.2 after 20 minutes, 67.9 ± 3.9 after 30 minutes, and 87.8 ± 2.0 after 40 minutes of ischemia, respectively. PC significantly reduced %IS/RA after 20, 30, and 40 minutes of ischemia to 3.1 ± 0.8, 12.8 ± 1.1, and 42.1 ± 4.3, respectively (P < 0.05 vs. each control). Naloxone (6 mg/kg) partially attenuated the protection afforded by PC when the sustained ischemia was 30 minutes (%IS/RA = 27.4 ± 4.5; P < 0.05 vs. PC), but this inhibitory effect of naloxone was not detected when the duration of the ischemia was 20 or 40 minutes. NTI (10 mg/kg) also attenuated infarct size limitation by PC after 30 minutes of ischemia (%IS/RA = 25.6 ± 3.7), but nor-BNI (10 mg/kg) failed to modify infarct size limitation by PC (%IS/RA = 13.3 ± 3.2). The present results suggest that activation of the opioid δ-receptor partly contributes to preconditioning against infarction in the rat and that there may be a time window (at around 30 minutes after the onset of ischemia) for this opioid receptor–mediated protective mechanism.
Similar content being viewed by others
References
Liu GS, Thornton JD, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in the rabbit heart. Circulation 1991;84:350-356.
Tsuchida A, Miura T, Miki T, Shimamoto K, Iimura O. Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning. Cardiovasc Res 1992;26:456-461.
Van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, Davis RF. Cardioprotection provided by adenosine receptor activation is abolished by blockade of the KATP channel. Am J Physiol 1994;266:H829-839.
Kitakaze M, Takashima S, Morioka T, Sato H, Hori M. α1 adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity. J Clin Invest 1994;93:2197-2205.
Tanaka M, Fujiwara H, Yamasaki K, Sasayama S. Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate the infarct size-limiting effect of ischaemic preconditioning in the rabbit. Cardiovasc Res 1994;28:980-986.
Li Y, Kloner RA. The cardioprotective effects of ischemic “preconditioning” are not mediated by adenosine receptors in rat hearts. Circulation 1993;87:1642-1648.
Liu Y, Downey JM. Ischemic preconditioning protects against infarction in the rat heart. Am J Physiol 1992;263: H1107-H1112.
Tsuchida A, Miura T, Miki T, Sakamoto J, Iimura O. Role of α1 receptor and protein kinase C in infarct size limitation by ischemic preconditioning in the rat heart (abstr). Circulation 1994;90:I-647.
Richard V, Tron C, Thuillez C. Ischaemic preconditioning is not mediated by oxygen-derived free radicals in rats. Cardiovasc Res 1993;27:2016-2021.
Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: Its role in ischemic preconditioning in the rat. Circ Res 1994;75:586-590.
Li Y, Kloner RA. Does protein kinase C play a role in ischemic preconditioning in rat hearts? Am J Physiol 1995; 268:H426-H431.
Gross GJ, Schultz JJ. Glibenclamide abolishes ischemic preconditioning in a time-dependent manner in the rat heart (abstr). FASEB J 1996;10:A140.
Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-233.
Ytrehus K, Liu Y, Downey JM. Preconditioning protects the ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994;266, H1145-1152.
Schultz JJ, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995;268:H2157-H2161.
Schultz JJ, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996; 78:1100-1104.
Wittert G, Hope P, Pyle D. Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun 1996;218:877-881.
Portoghese PS, Sultana M, Takemori AE. Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur J Pharmacol 1988;146:185-186.
Muhammad BY, Kitchen I. Effect of delayed weaning on opioid receptor control of swim stress-induced antinociception in the developing rat. Br J Pharmacol 1993;109:651-654.
Negus SS, Henriksen SJ, Mattox A, et al. Effect of antagonist selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats. J Pharmacol Exp Ther 1993;265:1245-1252.
Takemori AE, Ho YH, Naeseth JS, Portoghese PS. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 1988;246:255-258.
Takemori AE, Schwartz MM, Portoghese PS. Suppression by nor-binaltorphimine of kappa opioid-mediated diuresis in rats. Pharmacol Exp Ther 1988;247:971-974.
Jeffe JH, Martin RM. Opioid analgesics and antagonists. In: Goodman, Gilman A, Rall TW, Nies AS, Taylor P (eds). The Pharmacological Basis of Therapeutics. New York: Pergamon Press, 1990:485-521.
Miki T, Sato H, Cohen MV, Downey JM. Opioid receptor contributes to ischemic preconditioning though protein kinase C activation in rabbits (abstr). Circulation 1996;94: I-392.
Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Moll Cell Cardiol 1997;29: 207-216.
Miura T, Miura T, Kawamura S, et al. Effect of protein kinase C inhibitors on cardioprotection by ischemic preconditioning depends on the number of preconditioning episodes. Cardiovasc Res, 1998;37:700-709.
Giugliano D, Cozzolino D, Salvatore T, et al. Physiological elevations of plasma beta-endorphin alter glucose metabolism in obese, but not normal-weight, subjects. Metabolism 1992;41:194-190.
Boluyt MO, Younes A, Caffrey JL, O'Neill L, Barron BA, Crow MT, Lakatta EG. Age-associated increase in rat cardiac opioid production. Am J Physiol 1993;265:H212-H218.
Denavit-Saubie M, Champagnat J, Zieglansberger W. Effects of opiates and methionine-enkephaline on pontine and bulbar respiratory neurones of the cat. Brain Res 1978;155: 57-67.
Benndorf K, Thierfelder S., Doepner B, Gebhardt C, Hirche H. Role of cardiac KATP channels during anoxia and ischemia. New Physiol Sci 1997;12:78-83.
Thierfelder S, Doepner B, Gebhardt C, Hirche H, Benndorf K. ATP-sensitive K+ channels in heart muscle cells first open and subsequently close at maintained anoxia. FEBS Lett 1994;351:365-369.
Magnan J, Paterson SJ, Tavani A, Kosterlitz HW. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedebergs Arch Phamacol 1982;319:197-205.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsuchida, A., Miura, T., Tanno, M. et al. Time Window for the Contribution of the δ-opioid Receptor to Cardioprotection by Ischemic Preconditioning in the Rat Heart. Cardiovasc Drugs Ther 12, 365–373 (1998). https://doi.org/10.1023/A:1007720801004
Issue Date:
DOI: https://doi.org/10.1023/A:1007720801004